Stocksigma LogoStocksigma Logo

Bliss GVS Pharma Board Approves Two New ESOP Schemes

Bliss GVS Pharma鈥檚 board approved the adoption of the Senior Executive ESOP 2026 and Employee ESOP 2026 on 1st Oct'26, subject to shareholder approval

Bliss GVS Pharma Board Approves Two New ESOP Schemes

Bliss GVS Pharma Ltd 路 Outcome 路 02 Oct 2026, 1:16 am

Bliss GVS Pharma Board Approves Two New ESOP Schemes Bliss GVS Pharma鈥檚 board approved the adoption of the Senior Executive ESOP 2026 and Employee ESOP 2026 on 1st Oct'26, subject to shareholder approval. The Senior Executive ESOP 2026 covers up to 26,50,000 equity shares (~2.49% of paid-up equity), while the Employee ESOP 2026 covers up to 47,00,000 equity shares (~4.42% of paid-up equity) on a fully diluted basis. Both schemes carry a fixed discounted exercise price of INR 10 per share with a minimum one-year vesting period.

Original exchange filing (PDF)

More announcements from Bliss GVS Pharma Ltd

All Bliss GVS Pharma Ltd announcements